Goldman Sachs’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.18M Sell
52,400
-291,100
-85% -$17M ﹤0.01% 4125
2025
Q4
$18.5M Hold
343,500
﹤0.01% 2459
2025
Q3
$15.5M Sell
343,500
-147,100
-30% -$6.87M ﹤0.01% 2515
2025
Q2
$22.7M Buy
490,600
+71,100
+17% +$3.49M ﹤0.01% 2015
2025
Q1
$25.6M Sell
419,500
-454,500
-52% -$26.5M ﹤0.01% 1784
2024
Q4
$49.4M Buy
874,000
+509,000
+139% +$28.4M 0.01% 1301
2024
Q3
$18.9M Hold
365,000
﹤0.01% 2121
2024
Q2
$15.2M Sell
365,000
-91,200
-20% -$4.08M ﹤0.01% 2116
2024
Q1
$24.7M Buy
456,200
+82,500
+22% +$4.2M ﹤0.01% 1659
2023
Q4
$19.2M Buy
373,700
+76,100
+26% +$3.99M ﹤0.01% 1940
2023
Q3
$17.3M Buy
297,600
+83,300
+39% +$5.1M ﹤0.01% 1936
2023
Q2
$13.7M Buy
214,300
+108,400
+102% +$7.27M ﹤0.01% 2168
2023
Q1
$7.34M Sell
105,900
-40,900
-28% -$2.88M ﹤0.01% 2700
2022
Q4
$10.6M Buy
146,800
+60,100
+69% +$4.53M ﹤0.01% 2528
2022
Q3
$6.16M Sell
86,700
-143,400
-62% -$10.4M ﹤0.01% 2951
2022
Q2
$17.7M Buy
230,100
+99,200
+76% +$7.56M ﹤0.01% 1998
2022
Q1
$9.56M Sell
130,900
-63,700
-33% -$4.28M ﹤0.01% 2740
2021
Q4
$12.1M Buy
194,600
+25,300
+15% +$1.48M ﹤0.01% 2585
2021
Q3
$10M Sell
169,300
-927,600
-85% -$61.1M ﹤0.01% 2721
2021
Q2
$73.3M Buy
1,096,900
+669,200
+156% +$43.6M 0.02% 962
2021
Q1
$27M Buy
427,700
+74,600
+21% +$4.64M 0.01% 1678
2020
Q4
$21.9M Buy
353,100
+210,400
+147% +$12.9M 0.01% 1772
2020
Q3
$8.6M Buy
142,700
+14,500
+11% +$873K ﹤0.01% 2449
2020
Q2
$7.54M Buy
128,200
+30,200
+31% +$1.81M ﹤0.01% 2469
2020
Q1
$5.46M Sell
98,000
-1,927,000
-95% -$118M ﹤0.01% 2565
2019
Q4
$130M Buy
2,025,000
+1,382,500
+215% +$79.2M 0.03% 575
2019
Q3
$32.6M Buy
642,500
+91,500
+17% +$4.3M 0.01% 1416
2019
Q2
$25M Sell
551,000
-1,781,600
-76% -$83M 0.01% 1675
2019
Q1
$111M Buy
2,332,600
+1,742,200
+295% +$86.8M 0.03% 595
2018
Q4
$30.7M Buy
590,400
+151,100
+34% +$8.12M 0.01% 1469
2018
Q3
$27.3M Sell
439,300
-209,200
-32% -$12.4M 0.01% 1692
2018
Q2
$35.9M Sell
648,500
-188,400
-23% -$10.2M 0.01% 1468
2018
Q1
$52.9M Buy
836,900
+176,300
+27% +$11.3M 0.01% 1154
2017
Q4
$40.5M Buy
660,600
+115,100
+21% +$7.2M 0.01% 1441
2017
Q3
$34.8M Sell
545,500
-271,600
-33% -$15.9M 0.01% 1543
2017
Q2
$45.5M Sell
817,100
-2,868,200
-78% -$156M 0.01% 1305
2017
Q1
$200M Buy
3,685,300
+2,166,000
+143% +$119M 0.05% 387
2016
Q4
$88.8M Buy
1,519,300
+136,300
+10% +$7.45M 0.03% 853
2016
Q3
$74.6M Buy
1,383,000
+5,000
+0.4% +$321K 0.02% 908
2016
Q2
$101M Sell
1,378,000
-331,700
-19% -$23.4M 0.03% 668
2016
Q1
$109M Buy
1,709,700
+1,191,500
+230% +$75.1M 0.04% 618
2015
Q4
$35.6M Sell
518,200
-1,107,800
-68% -$73.2M 0.01% 1359
2015
Q3
$96.3M Buy
1,626,000
+463,300
+40% +$29.4M 0.03% 643
2015
Q2
$77.4M Buy
1,162,700
+683,400
+143% +$45M 0.02% 820
2015
Q1
$30.9M Sell
479,300
-278,100
-37% -$17.4M 0.01% 1447
2014
Q4
$44.7M Buy
757,400
+56,000
+8% +$3.16M 0.01% 1200
2014
Q3
$35.9M Sell
701,400
-491,000
-41% -$24.5M 0.01% 1328
2014
Q2
$57.8M Buy
1,192,400
+105,500
+10% +$5.2M 0.02% 985
2014
Q1
$56.5M Sell
1,086,900
-748,300
-41% -$39.8M 0.02% 975
2013
Q4
$97.5M Buy
1,835,200
+735,400
+67% +$37.5M 0.03% 643
2013
Q3
$50.9M Sell
1,099,800
-78,000
-7% -$3.42M 0.02% 943
2013
Q2
$52.6M Buy
+1,177,800
New +$51.1M 0.02% 874

Other funds holding BMY

Goldman Sachs's BMY Position: Q1 2026 in Review

Goldman Sachs reduced its Bristol-Myers Squibb (BMY) stake by 23% in Q1 2026, selling an estimated $250M and leaving 14,054,518 shares worth $852M. The position accounts for 0.1% of the portfolio, ranked #196.

Goldman Sachs first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.19B in Q1 2023. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Goldman Sachs held 14,054,518 shares of Bristol-Myers Squibb worth $852M as of Q1 2026.
  • Goldman Sachs sold 4,288,459 Bristol-Myers Squibb shares in Q1 2026, an estimated $250M.
  • Bristol-Myers Squibb made up 0.1% of Goldman Sachs's portfolio in Q1 2026, its #196 holding.
  • Goldman Sachs first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Bristol-Myers Squibb position peaked at $1.19B in Q1 2023.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.